The Peptide Trade: A $164 Billion Market, a Regulatory Thaw, and a Setup Crypto Investors Will Recognize

On April 16, Health and Human Services Secretary Robert F. Kennedy Jr. confirmed the FDA will convene its Pharmacy Compounding Advisory Committee in July to reconsider a slate of peptides the Biden-era FDA designated as “Category 2” — bulk drug substances flagged for “significant safety risks.” A second panel is scheduled for February 2027. Twelve peptides are on the docket: BPC-157, Thymosin beta-4 fragment (LKKTETQ), Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, Ibutamoren Mesylate, Melanotan II, KPV, Semax, and Cathelicidin LL-37.

Today, we took long-overdue action to restore science, accountability, and the rule of law, said Kennedy, source: X

To anyone who watched crypto’s regulatory cycle, the political economy is recognizable. A previous administration treated the category as inherently suspect and pushed users offshore. A new administration argues the restriction created the very problem it was meant to solve and is reopening the regulated channel. “We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve,” Kennedy said in his April statement. Critics aren’t convinced. “Everybody knows the outcome that the secretary wants,” Peter Lurie, a former FDA associate commissioner, told NBC News, arguing the review is unlikely to produce honest scrutiny. Bitcoin maximalists made the same argument about the SEC’s 2024 about-face, and the price action didn’t care.

The setup, in markets terms

Peptide therapeutics — short chains of amino acids that act as biological signaling molecules — are not a fringe category. The global market was valued at roughly $141 billion in 2025 and is projected to reach about $164 billion this year, on track to nearly double to $295 billion by 2033. Insulin is a peptide. So is semaglutide. So is tirzepatide. The branded, FDA-approved end of the market is one of pharma’s largest and fastest-growing categories.

The contested end — the twelve compounds on Kennedy’s list — sits in the same regulatory shadow that offshore crypto exchanges occupied circa 2022. Compounding pharmacies were preparing peptides under the FDA’s Section 503A framework until the 2023 Category 2 reclassification effectively shut them out. Demand didn’t disappear; it routed offshore. TikTok and Telegram vendors now sell vials labeled “research use only” for as little as $5, most of them sourced from Chinese laboratories outside U.S. drug standards. The parallel to unregulated offshore exchanges, sanctions-evading mixers, and crypto’s grey supply chain isn’t subtle. The regulated US channel got squeezed; demand migrated to jurisdictions where quality is whatever the seller says it is.

The retail demand signal is also familiar. Google search interest in “peptides” rose 80% in the United States between April 2025 and April 2026, according to trend data compiled by Open Loop Health, with queries for “cost of peptide therapy” up 300%. Joe Rogan and Andrew Huberman are doing for BPC-157 what Michael Saylor and Anthony Pompliano did for Bitcoin: pulling a category into mainstream consciousness through high-trust audiences well before the regulatory framework catches up.

The spot-ETF moment

What makes this more than a wellness trend is what’s happening at the institutional end of the same molecule class.

Eli Lilly’s investigational triple-receptor agonist retatrutide — itself a synthetic peptide — has produced the most dramatic obesity trial results on record. In December, Lilly’s TRIUMPH-4 study reported average weight loss of up to 23.7% (about 60 pounds) at the highest dose over 68 weeks, alongside significant reductions in osteoarthritis knee pain. A March 2026 Type 2 diabetes readout showed up to 17% weight loss and 2-point A1c reductions at 40 weeks. Seven additional Phase 3 readouts are expected through year-end, with FDA filing anticipated Q4 2026 or Q1 2027.

For peptides as an asset class, retatrutide is the equivalent of BlackRock filing for IBIT. Once a major institution proves the thesis can clear the highest bar — a Phase 3 trial, a spot ETF — the category gets re-rated. Capital that previously stayed away on credibility grounds starts looking for adjacent exposure. The wider peptide thesis no longer rests on Rogan-podcast anecdotes; it rests on data from a $700 billion drugmaker.

The investable surface

The publicly tradable proxies are already moving. Hims & Hers shares jumped on Kennedy’s April announcement on the view that compounded peptides could become the next growth lane after GLP-1s, with Leerink calling it a clearer regulatory path to scale. The setup mirrors the Coinbase trade: a public-equity vehicle whose valuation tracks the regulatory tailwind for the underlying category.

The infrastructure layer is moving harder. Lilly is committing more than $6 billion to a new active pharmaceutical ingredient plant in Huntsville, Alabama, with peptide manufacturing as a core mandate. CordenPharma, Cambrex, and Lupin Manufacturing Solutions have all expanded peptide capacity in the past 12 months. In capital-allocation terms, this is the Strategy / Marathon move — operators making multi-billion-dollar bets on a category continuing to compound for a decade. Branded peptide therapeutics already account for more than 60% of the segment’s revenue, with North America holding roughly 38% of the global market.

Where crypto and peptides actually overlap

There is also a direct on-chain expression of the peptide thesis. VitaDAO, the decentralized longevity-research collective, has spent the past several years funding early-stage aging and longevity science through community governance, with its VITA token coordinating treasury decisions. PoSciDonDAO, profiled previously by BNC, runs a similar model for personalized medicine research funding. The Venn diagram between crypto-native investors and longevity bettors — Bryan Johnson’s audience, the Rogan-Huberman demographic, the Balaji Srinivasan thesis — overlaps almost entirely. DeSci tokens are, in a real sense, the only liquid way to express a longevity-science thesis at the protocol level. As the peptide category re-rates, that adjacent on-chain market is one of the more interesting beta plays on the same macro story.

The top six on the slate

Of the twelve peptides under FDA review, six dominate the clinical and consumer conversation:

BPC-157 — Synthetic fragment of a gastric-juice protein, used for tendon, ligament, and gut healing. Animal data extensive, human trials sparse. Almost certainly the headline name at the July panel.

GHK-Cu (copper peptide) — Naturally occurring tripeptide used both in skincare and as an injectable for wound healing and skin remodeling. Among the better-evidenced peptides on the list.

Epitalon — Soviet-developed four–amino-acid peptide marketed as a telomerase activator. Thin human data, mostly from a single research group. Flagship of the longevity-clinic circuit.

MOTS-c — Mitochondrial-derived peptide with credible academic interest in metabolic regulation and exercise mimicry. Mechanistic story is strong; Phase 3 data does not yet exist.

Thymosin beta-4 fragment (LKKTETQ) — Active fragment of TB-500, used for soft-tissue repair. Parent compound studied in early cardiac and corneal trials.

Ibutamoren (MK-677) — Technically a non-peptide growth-hormone secretagogue but bundled with the cohort. Clearest pharmacology, most documented side effects: water retention, insulin resistance, increased appetite.

The remaining six — DSIP, Dihexa, Melanotan II, KPV, Semax, and Cathelicidin LL-37 — span sleep, cognition, tanning, gut inflammation, and antimicrobial defense.

Risks that should sound familiar

The bear case mirrors crypto’s. The advisory committee is non-binding; rulemaking takes months; the FDA panel currently has multiple vacancies Kennedy can fill before July, raising legitimate process concerns. Most of the twelve peptides have minimal Phase 3 human data and no patent path that would justify building one. Quality control in the existing market is poor — counterparty risk in peptide vials is a meaningful problem the way self-custody-vs-exchange risk is in crypto. And political reversibility cuts both ways: what one administration unlocks, another can re-restrict.

What the bull case has going for it is the same thing crypto’s bull case had in early 2024: real capital is being deployed against the thesis at scale. Lilly’s $6 billion plant doesn’t get built on a regulatory whim. The peptide market is on track to add roughly $130 billion in value over the next decade with or without Kennedy’s Category 2 reversal. The reversal just determines who captures it — regulated U.S. compounders and telehealth platforms, or offshore vendors with TikTok storefronts. For investors looking past the next quarter, the trade isn’t whether peptides matter. It’s whether the legitimate end of the supply chain finally gets to participate.